Pulmonary embolism

Lancet

Volumn 363, Issue 9417, 2004, Pages 1295-1305

  Goldhaber, Samuel Z ^a,b  

^a HARVARD MEDICAL SCHOOL   (United States)

^b BRIGHAM AND WOMEN S HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; ANTICOAGULANT AGENT; ARGATROBAN; D DIMER; DALTEPARIN; DESOGESTREL; ENOXAPARIN; ESTROGEN; FONDAPARINUX; GESTAGEN; HEPARIN; HIRUDIN; LOW MOLECULAR WEIGHT HEPARIN; ORAL CONTRACEPTIVE AGENT; PROGESTERONE; RALOXIFENE; REVIPARIN; THROMBIN INHIBITOR; TINZAPARIN; TROPONIN; WARFARIN; XIMELAGATRAN;

ACCURACY; ANTICOAGULATION; BLEEDING; BLOOD CLOT LYSIS; BLOOD PRESSURE; BREAST CANCER; CARDIOGENIC SHOCK; CAUSE OF DEATH; CLINICAL TRIAL; COMPUTER ASSISTED TOMOGRAPHY; CONFERENCE PAPER; DEEP VEIN THROMBOSIS; DISABILITY; DISEASE PREDISPOSITION; DRUG METABOLISM; DRUG SAFETY; ECHOCARDIOGRAPHY; EMBOLECTOMY; HEART DISEASE; HEART RIGHT VENTRICLE; HEMODYNAMICS; HIGH RISK POPULATION; HOSPITAL DISCHARGE; HUMAN; LUNG EMBOLISM; META ANALYSIS; OBESITY; PRIORITY JOURNAL; RECURRENT DISEASE; RISK FACTOR; SCREENING TEST; THROMBOCYTOPENIA; THROMBOPHILIA; TRAVEL; VENOUS THROMBOEMBOLISM;

EID: 1942471068     PISSN: 01406736     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0140-6736(04)16004-2     Document Type: Conference Paper

References (144)

1. Pineda L.A., Hathwar V.S., Grant B.J. Clinical suspicion of fatal pulmonary embolism. Chest. 120:2001;791-795.
2. Goldacre M.J., Roberts S., Yeates D., Griffith M. Hospital admission and mortality rates for venous thromboembolism in Oxford region, UK, 1975-98. Lancet. 355:2000;1968-1969.
3. Oger E. Incidence of venous thromboembolism: a community-based study in Western France. Thromb Haemost. 83:2000;657-660.
4. Silverstein M.D., Heit J.A., Mohr D.N., Petterson T.M., O'Fallon W.M., Melton LJ III. Trends in the incidence of deep vein thrombosis and pulmonary embolism: a 25-year population-based study. Arch Intern Med. 158:1998;585-593.
5. Tsai A.W., Cushman M., Rosamond W.D., Heckbert S.R., Polak J.F., Folsom A.R. Cardiovascular risk factors and venous thromboembolism incidence: the longitudinal investigation of thromboembolism etiology. Arch Intern Med. 162:2002;1182-1189.
6. Heit J.A., Silverstein M.D., Mohr D.N., Petterson T.M., O'Fallon W.M., Melton LJ III. Predictors of survival after deep vein thrombosis and pulmonary embolism: a population-based, cohort study. Arch Intern Med. 159:1999;445-453.
7. Goldhaber S.Z., Visani L., De Rosa M. Acute pulmonary embolism: clinical outcomes in the International Cooperative Pulmonary Embolism Registry (ICOPER). Lancet. 353:1999;1386-1389.
8. Nakamura M., Fujioka H., Yamada N., et al. Clinical characteristics of acute pulmonary thromboembolism in Japan: results of a multicenter registry in the Japanese Society of Pulmonary Embolism Research. Clin Cardiol. 24:2001;132-138.
9. van Beek E.J., Kuijer P.M., Buller H.R., Brandjes D.P., Bossuyt P.M., ten Cate J.W. The clinical course of patients with suspected pulmonary embolism. Arch Intern Med. 157:1997;2593-2598.
10. Carson J.L., Kelley M.A., Duff A., et al. The clinical course of pulmonary embolism. N Engl J Med. 326:1992;1240-1245.
11. Douketis J.D., Kearon C., Bates S., Duku E.K., Ginsberg J.S. Risk of fatal pulmonary embolism in patients with treated venous thromboembolism. JAMA. 279:1998;458-462.
12. Samama M.M. An epidemiologic study of risk factors for deep vein thrombosis in medical outpatients: the Sirius study. Arch Intern Med. 160:2000;3415-3420.
13. Anderson F.A. Jr, Spencer F.A. Risk factors for venous thromboembolism. Circulation. 107:2003;I9-I16.
14. Lapostolle F., Surget V., Borron S.W., et al. Severe pulmonary embolism associated with air travel. N Engl J Med. 345:2001;779-783.
15. Goldhaber S.Z., Grodstein F., Stampfer M.J., et al. A prospective study of risk factors for pulmonary embolism in women. JAMA. 277:1997;642-645.
16. Rosing J., Middeldorp S., Curvers J., et al. Low-dose oral contraceptives and acquired resistance to activated protein C: a randomised cross-over study. Lancet. 354:1999;2036-2040.
17. Vandenbroucke J.P., Rosing J., Bloemenkamp K.W., et al. Oral contraceptives and the risk of venous thrombosis. N Engl J Med. 344:2001;1527-1535.
18. Parkin L., Skegg D.C., Wilson M., Herbison G.P., Paul C. Oral contraceptives and fatal pulmonary embolism. Lancet. 355:2000;2133-2134.
19. Greer I.A. Thrombosis in pregnancy: maternal and fetal issues. Lancet. 353:1999;1258-1265.
20. Kupferminc M.J., Eldor A., Steinman N., et al. Increased frequency of genetic thrombophilia in women with complications of pregnancy. N Engl J Med. 340:1999;9-13.
21. Martinelli I., De Stefano V., Taioli E., Paciaroni K., Rossi E., Mannucci P.M. Inherited thrombophilia and first venous thromboembolism during pregnancy and puerperium. Thromb Haemost. 87:2002;791-795.
22. Women's Health Initiative Investigators. Risks and benefits of estrogen plus progestin in healthy postmenopausal women: principal results from the Women's Health Initiative randomized controlled trial. JAMA 2002; 288: 321-333.
23. Nelson H.D., Humphrey L.L., Nygren P., Teutsch S.M., Allan J.D. Postmenopausal hormone replacement therapy: scientific review. JAMA. 288:2002;872-881.
24. Cummings S.R., Eckert S., Krueger K.A., et al. The effect of raloxifene on risk of breast cancer in postmenopausal women: results from the MORE randomized trial. JAMA. 281:1999;2189-2197.
25. Cuzick J., Forbes J., Edwards R., et al. First results from the International Breast Cancer Intervention Study (IBIS-I): a randomised prevention trial. Lancet. 360:2002;817-824.
26. Prandoni P., Lensing A.W., Piccioli A., et al. Recurrent venous thromboembolism and bleeding complications during anticoagulant treatment in patients with cancer and venous thrombosis. Blood. 100:2002;3484-3488.
27. Lee A.Y., Levine M.N., Baker R.I., et al. Low-molecular-weight heparin versus a coumarin for the prevention of recurrent venous thromboembolism in patients with cancer. N Engl J Med. 349:2003;146-153.
28. Schulman S., Lindmarker P. Incidence of cancer after prophylaxis with warfarin against recurrent venous thromboembolism: Duration of Anticoagulation Trial. N Engl J Med. 342:2000;1953-1958.
29. Sorensen H.T., Mellemkjaer L., Olsen J.H., Baron J.A. Prognosis of cancers associated with venous thromboembolism. N Engl J Med. 343:2000;1846-1850.
30. Prandoni P., Lensing A.W., Buller H.R., et al. Deep-vein thrombosis and the incidence of subsequent symptomatic cancer. N Engl J Med. 327:1992;1128-1133.
31. Seligsohn U., Lubetsky A. Genetic susceptibility to venous thrombosis. N Engl J Med. 344:2001;1222-1231.
32. Ariens R.A., de Lange M., Snieder H., Boothby M., Spector T.D., Grant P.J. Activation markers of coagulation and fibrinolysis in twins: heritability of the prethrombotic state. Lancet. 359:2002;667-671.
33. Price D.T., Ridker P.M. Factor V Leiden mutation and the risks for thromboembolic disease: a clinical perspective. Ann Intern Med. 127:1997;895-903.
34. Ridker P.M., Miletich J.P., Hennekens C.H., Buring J.E. Ethnic distribution of factor V Leiden in 4047 men and women: implications for venous thromboembolism screening. JAMA. 277:1997;1305-1307.
35. Simioni P., Prandoni P., Lensing A.W., et al. The risk of recurrent venous thromboembolism in patients with an Arg506→Gln mutation in the gene for factor V (factor V Leiden). N Engl J Med. 336:1997;399-403.
36. De Stefano V., Martinelli I., Mannucci P.M., et al. The risk of recurrent deep venous thrombosis among heterozygous carriers of both factor V Leiden and the G20210A prothrombin mutation. N Engl J Med. 341:1999;801-806.
37. Poort S.R., Rosendaal F.R., Reitsma P.H., Bertina R.M. A common genetic variation in the 3′-untranslated region of the prothrombin gene is associated with elevated plasma prothrombin levels and an increase in venous thrombosis. Blood. 88:1996;3698-3703.
38. Ridker P.M., Hennekens C.H., Miletich J.P. G20210A mutation in prothrombin gene and risk of myocardial infarction, stroke, and venous thrombosis in a large cohort of US men. Circulation. 99:1999;999-1004.
39. Hankey G.J., Eikelboom J.W. Homocysteine and vascular disease. Lancet. 354:1999;407-413.
40. Levine J.S., Branch D.W., Rauch J. The antiphospholipid syndrome. N Engl J Med. 346:2002;752-763.
41. Middeldorp S., Henkens C.M., Koopman M.M., et al. The incidence of venous thromboembolism in family members of patients with factor V Leiden mutation and venous thrombosis. Ann Intern Med. 128:1998;15-20.
42. Joffe H.V., Goldhaber S.Z. Upper-extremity deep vein thrombosis. Circulation. 106:2002;1874-1880.
43. Wood K.E. Major pulmonary embolism: review of a pathophysiologic approach to the golden hour of hemodynamically significant pulmonary embolism. Chest. 121:2002;877-905.
44. Wells P.S., Anderson D.R., Rodger M., et al. Derivation of a simple clinical model to categorize patients probability of pulmonary embolism: increasing the models utility with the SimpliRED D-dimer. Thromb Haemost. 83:2000;416-420.
45. Daniel K.R., Courtney D.M., Kline J.A. Assessment of cardiac stress from massive pulmonary embolism with 12-lead ECG. Chest. 120:2001;474-481.
46. Pistolesi M., Miniati M. Imaging techniques in treatment algorithms of pulmonary embolism. Eur Respir J. 19:2002;28s-39s.
47. Stein P.D., Goldhaber S.Z., Henry J.W., Miller A.C. Arterial blood gas analysis in the assessment of suspected acute pulmonary embolism. Chest. 109:1996;78-81.
48. Stein P.D., Goldhaber S.Z., Henry J.W. Alveolar-arterial oxygen gradient in the assessment of acute pulmonary embolism. Chest. 107:1995;139-143.
49. Kelly J., Hunt B.J. Role of D-dimers in diagnosis of venous thromboembolism. Lancet. 359:2002;456-458.
50. Dunn K.L., Wolf J.P., Dorfman D.M., Fitzpatrick P., Baker J.L., Goldhaber S.Z. Normal D-dimer levels in emergency department patients suspected of acute pulmonary embolism. J Am Coll Cardiol. 40:2002;1475-1478.
51. Wells P.S., Anderson D.R., Rodger M., et al. Excluding pulmonary embolism at the bedside without diagnostic imaging: management of patients with suspected pulmonary embolism presenting to the emergency department by using a simple clinical model and d-dimer. Ann Intern Med. 135:2001;98-107.
52. Perrier A., Desmarais S., Miron M.J., et al. Non-invasive diagnosis of venous thromboembolism in outpatients. Lancet. 353:1999;190-195.
53. Konstantinides S., Geibel A., Olschewski M., et al. Importance of cardiac troponins I and T in risk stratification of patients with acute pulmonary embolism. Circulation. 106:2002;1263-1268.
54. Kucher N., Printzen G., Doernhoefer T., Windecker S., Meier B., Hess O.M. Low pro-brain natriuretic peptide levels predict benign clinical outcome in acute pulmonary embolism. Circulation. 107:2003;1576-1578.
55. ten Wolde M., Tulevski I.I., Mulder J.W., et al. Brain natriuretic peptide as a predictor of adverse outcome in patients with pulmonary embolism. Circulation. 107:2003;2082-2084.
56. Kucher N., Printzen G., Goldhaber S.Z. Prognostic role of brain natriuretic peptide in acute pulmonary embolism. Circulation. 107:2003;2545-2556.
57. PIOPED Investigators. Value of the ventilation/perfusion scan in acute pulmonary embolism: results of the prospective investigation of pulmonary embolism diagnosis (PIOPED). JAMA 1990; 263: 2753-2759.
58. Perrier A., Howarth N., Didier D., et al. Performance of helical computed tomography in unselected outpatients with suspected pulmonary embolism. Ann Intern Med. 135:2001;88-97.
59. Qanadli S.D., Hajjam M.E., Mesurolle B., et al. Pulmonary embolism detection: prospective evaluation of dual-section helical CT versus selective pulmonary arteriography in 157 patients. Radiology. 217:2000;447-455.
60. Oudkerk M., van Beek E.J., Wielopolski P., et al. Comparison of contrast-enhanced magnetic resonance angiography and conventional pulmonary angiography for the diagnosis of pulmonary embolism: a prospective study. Lancet. 359:2002;1643-1647.
61. Turkstra F., Kuijer P.M., van Beek E.J., Brandjes D.P., ten Cate J.W., Buller H.R. Diagnostic utility of ultrasonography of leg veins in patients suspected of having pulmonary embolism. Ann Intern Med. 126:1997;775-781.
62. Miniati M., Monti S., Pratali L., et al. Value of transthoracic echocardiography in the diagnosis of pulmonary embolism: results of a prospective study in unselected patients. Am J Med. 110:2001;528-535.
63. Stein P.D., Athanasoulis C., Alavi A., et al. Complications and validity of pulmonary angiography in acute pulmonary embolism. Circulation. 85:1992;462-468.
64. van Beek E.J., Brouwerst E.M., Song B., Stein P.D., Oudkerk M. Clinical validity of a normal pulmonary angiogram in patients with suspected pulmonary embolism: a critical review. Clin Radiol. 56:2001;838-842.
65. Gottschalk A., Stein P.D., Goodman L.R., Sostman H.D. Overview of prospective investigation of pulmonary embolism diagnosis II. Semin Nucl Med. 32:2002;173-182.
66. Wicki J., Perrier A., Perneger T.V., Bounameaux H., Junod A.F. Predicting adverse outcome in patients with acute pulmonary embolism: a risk score. Thromb Haemost. 84:2000;548-552.
67. Goldhaber S.Z. Echocardiography in the management of pulmonary embolism. Ann Intern Med. 136:2002;691-700.
68. Grifoni S., Olivotto I., Cecchini P., et al. Short-term clinical outcome of patients with acute pulmonary embolism, normal blood pressure, and echocardiographic right ventricular dysfunction. Circulation. 101:2000;2817-2822.
69. Ribeiro A., Lindmarker P., Johnsson H., Juhlin-Dannfelt A., Jorfeldt L. Pulmonary embolism: one-year follow-up with echocardiography doppler and five-year survival analysis. Circulation. 99:1999;1325-1330.
70. Hirsh J., Anand S.S., Halperin J.L., Fuster V. Guide to anticoagulant therapy - heparin: a statement for healthcare professionals from the American Heart Association. Circulation. 103:2001;2994-3018.
71. Bernardi E., Piccioli A., Oliboni G., Zuin R., Girolami A., Prandoni P. Nomograms for the administration of unfractionated heparin in the initial treatment of acute thromboembolism: an overview. Thromb Haemost. 84:2000;22-26.
72. Agnelli G., Iorio A., Renga C., et al. Prolonged antithrombin activity of low-molecular-weight heparins: clinical implications for the treatment of thromboembolic diseases. Circulation. 92:1995;2819-2824.
73. Columbus Investigators. Low-molecular-weight heparin in the treatment of patients with venous thromboembolism. N Engl J Med 1997; 337: 657-662.
74. Simonneau G., Sors H., Charbonnier B., et al. A comparison of low-molecular-weight heparin with unfractionated heparin for acute pulmonary embolism. N Engl J Med. 337:1997;663-669.
75. Merli G., Spiro T.E., Olsson C.G., et al. Subcutaneous enoxaparin once or twice daily compared with intravenous unfractionated heparin for treatment of venous thromboembolic disease. Ann Intern Med. 134:2001;191-202.
76. Breddin H.K., Hach-Wunderle V., Nakov R., Kakkar V.V. Effects of a low-molecular-weight heparin on thrombus regression and recurrent thromboembolism in patients with deep-vein thrombosis. N Engl J Med. 344:2001;626-631.
77. Warkentin T.E. Heparin-induced thrombocytopenia: yet another treatment paradox? Thromb Haemost. 85:2001;947-949.
78. Greinacher A., Volpel H., Janssens U., et al. Recombinant hirudin (lepirudin) provides safe and effective anticoagulation in patients with heparin-induced thrombocytopenia: a prospective study. Circulation. 99:1999;73-80.
79. Lewis B.E., Wallis D.E., Berkowitz S.D., et al. Argatroban anticoagulant therapy in patients with heparin-induced thrombocytopenia. Circulation. 103:2001;1838-1843.
80. Warkentin T.E., Kelton J.G. Temporal aspects of heparin-induced thrombocytopenia. N Engl J Med. 344:2001;1286-1292.
81. Rice L., Attisha W.K., Drexler A., Francis J.L. Delayed-onset heparin-induced thrombocytopenia. Ann Intern Med. 136:2002;210-215.
82. Hylek E.M., Heiman H., Skates S.J., Sheehan M.A., Singer D.E. Acetaminophen and other risk factors for excessive warfarin anticoagulation. JAMA. 279:1998;657-662.
83. Crowther M.A., Ginsberg J.B., Kearon C., et al. A randomized trial comparing 5-mg and 10-mg warfarin loading doses. Arch Intern Med. 159:1999;46-48.
84. Higashi M.K., Veenstra D.L., Kondo L.M., et al. Association between CYP2C9 genetic variants and anticoagulation-related outcomes during warfarin therapy. JAMA. 287:2002;1690-1698.
85. Brummel K.E., Paradis S.G., Branda R.F., Mann K.G. Oral anticoagulation thresholds. Circulation. 104:2001;2311-2317.
86. Crowther M.A., Douketis J.D., Schnurr T., et al. Oral vitamin K lowers the international normalized ratio more rapidly than subcutaneous vitamin K in the treatment of warfarin-associated coagulopathy: a randomized, controlled trial. Ann Intern Med. 137:2002;251-254.
87. Pengo V., Legnani C., Noventa F., Palareti G. Oral anticoagulant therapy in patients with nonrheumatic atrial fibrillation and risk of bleeding: a multicenter inception cohort study. Thromb Haemost. 85:2001;418-422.
88. Cromheecke M.E., Levi M., Colly L.P., et al. Oral anticoagulation self-management and management by a specialist anticoagulation clinic: a randomised cross-over comparison. Lancet. 356:2000;97-102.
89. Ridker P.M., Goldhaber S.Z., Danielson E., et al. Long-term, low-intensity warfarin therapy for the prevention of recurrent venous thromboembolism. N Engl J Med. 348:2003;1425-1434.
90. Kearon C., Ginsberg J.S., Kovacs M.J., et al. Comparison of low-intensity warfarin therapy with conventional-intensity warfarin therapy for long-term prevention of recurrent venous thromboembolism. N Engl J Med. 349:2003;631-639.
91. Schulman S, Wåhlander K, Lundström T, Clason SB, Eriksson H, for the THRIVE III Investigators. Secondary prevention of venous thromboembolism with the oral direct thrombin inhibitor ximelagatran. N Engl J Med 2003; 349: 1713-1721.
92. Konstantinides S, Geibel A, Heusel G, Heinrich F, Kasper W, for the Management Strategies and Prognosis of Pulmonary Embolism-3 Trial Investigators. Heparin plus alteplase compared with heparin alone in patients with submassive pulmonary embolism. N Engl J Med 2002; 347: 1143-1150.
93. Goldhaber S.Z. Thrombolysis for pulmonary embolism. N Engl J Med. 347:2002;1131-1132.
94. Thabut G., Thabut D., Myers R.P., et al. Thrombolytic therapy of pulmonary embolism: a meta-analysis. J Am Coll Cardiol. 40:2002;1660-1667.
95. Dalen J.E. Thrombolysis in submassive pulmonary embolism? No. J Thromb Haemost. 1:2003;1130-1132.
96. Hamel E., Pacouret G., Vincentelli D., et al. Thrombolysis or heparin therapy in massive pulmonary embolism with right ventricular dilation: results from a 128-patient monocenter registry. Chest. 120:2001;120-125.
97. Meyer G., Koning R., Sors H. Transvenous catheter embolectomy. Semin Vasc Med. 1:2001;247-252.
98. Aklog L., Williams C.S., Byrne J.G., Goldhaber S.Z. Acute pulmonary embolectomy: a contemporary approach. Circulation. 105:2002;1416-1419.
99. Decousus H., Leizorovicz A., Parent F., et al. A clinical trial of vena caval filters in the prevention of pulmonary embolism in patients with proximal deep-vein thrombosis. N Engl J Med. 338:1998;409-415.
100. White R.H., Zhou H., Kim J., Romano P.S. A population-based study of the effectiveness of inferior vena cava filter use among patients with venous thromboembolism. Arch Intern Med. 160:2000;2033-2041.
101. Millward S.F., Oliva V.L., Bell S.D., et al. Gunther Tulip retrievable vena cava filter: results from the Registry of the Canadian Interventional Radiology Association. J Vasc Interv Radiol. 12:2001;1053-1058.
102. Heit J.A., Mohr D.N., Silverstein M.D., Petterson T.M., O'Fallon W.M., Melton LJ III. Predictors of recurrence after deep vein thrombosis and pulmonary embolism: a population-based cohort study. Arch Intern Med. 160:2000;761-768.
103. Hansson P.O., Sorbo J., Eriksson H. Recurrent venous thromboembolism after deep vein thrombosis: incidence and risk factors. Arch Intern Med. 160:2000;769-774.
104. Palareti G., Legnani C., Cosmi B., Guazzaloca G., Pancani C., Coccheri S. Risk of venous thromboembolism recurrence: high negative predictive value of D-dimer performed after oral anticoagulation is stopped. Thromb Haemost. 87:2002;7-12.
105. Prevention of venous thromboembolism: International Consensus Statement Guidelines compiled in accordance with the scientific evidence. Int Angiol 2001; 20: 1-37.
106. Geerts WH, Heit JA, Clagett GP, et al. Prevention of venous thromboembolism. Chest 2001; 119 (1 suppl): 132S-75S.
107. Durieux P., Nizard R., Ravaud P., Mounier N., Lepage E. A clinical decision support system for prevention of venous thromboembolism: effect on physician behavior. JAMA. 283:2000;2816-2821.
108. Dexter P.R., Perkins S., Overhage J.M., Maharry K., Kohler R.B., McDonald C.J. A computerized reminder system to increase the use of preventive care for hospitalized patients. N Engl J Med. 345:2001;965-970.
109. Goldhaber S.Z., Dunn K., MacDougall R.C. New onset of venous thromboembolism among hospitalized patients at Brigham and Women's Hospital is caused more often by prophylaxis failure than by withholding treatment. Chest. 118:2000;1680-1684.
110. Hirsch D.R., Ingenito E.P., Goldhaber S.Z. Prevalence of deep venous thrombosis among patients in medical intensive care. JAMA. 274:1995;335-337.
111. Goldhaber S.Z., Dunn K., Gerhard-Herman M., Park J.K., Black P.M. Low rate of venous thromboembolism after craniotomy for brain tumor using multimodality prophylaxis. Chest. 22:2003;1933-1937.
112. Samama M.M., Cohen A.T., Darmon J.Y., et al. A comparison of enoxaparin with placebo for the prevention of venous thromboembolism in acutely ill medical patients. N Engl J Med. 341:1999;793-800.
113. Mismetti P., Laporte-Simitsidis S., Tardy B., et al. Prevention of venous thromboembolism in internal medicine with unfractionated or low-molecular-weight heparins: a meta-analysis of randomised clinical trials. Thromb Haemost. 83:2000;14-19.
114. Bergqvist D., Agnelli G., Cohen A.T., et al. Duration of prophylaxis against venous thromboembolism with enoxaparin after surgery for cancer. N Engl J Med. 346:2002;975-980.
115. Bergqvist D., Benoni G., Bjorgell O., et al. Low-molecular-weight heparin (enoxaparin) as prophylaxis against venous thromboembolism after total hip replacement. N Engl J Med. 335:1996;696-700.
116. Planes A., Vochelle N., Darmon J.Y., Fagola M., Bellaud M., Huet Y. Risk of deep-venous thrombosis after hospital discharge in patients having undergone total hip replacement: double-blind randomised comparison of enoxaparin versus placebo. Lancet. 348:1996;224-228.
117. Colwell C.W. Jr, Collis D.K., Paulson R., et al. Comparison of enoxaparin and warfarin for the prevention of venous thromboembolic disease after total hip arthroplasty: evaluation during hospitalization and three months after discharge. J Bone Joint Surg Am. 81:1999;932-940.
118. Hull R.D., Pineo G.F., Francis C., et al. Low-molecular-weight heparin prophylaxis using dalteparin in close proximity to surgery vs warfarin in hip arthroplasty patients: a double- blind, randomized comparison. Arch Intern Med. 160:2000;2199-2207.
119. Hull R.D., Pineo G.F., Francis C., et al. Low-molecular-weight heparin prophylaxis using dalteparin extended out- of-hospital vs in-hospital warfarin/out-of-hospital placebo in hip arthroplasty patients: a double-blind, randomized comparison. Arch Intern Med. 160:2000;2208-2215.
120. Lassen M.R., Bauer K.A., Eriksson B.I., Turpie A.G. Postoperative fondaparinux versus preoperative enoxaparin for prevention of venous thromboembolism in elective hip-replacement surgery: a randomised double-blind comparison. Lancet. 359:2002;1715-1720.
121. Turpie A.G., Bauer K.A., Eriksson B.I., Lassen M.R. Postoperative fondaparinux versus postoperative enoxaparin for prevention of venous thromboembolism after elective hip-replacement surgery: a randomised double-blind trial. Lancet. 359:2002;1721-1726.
122. Leclerc J.R., Gent M., Hirsh J., Geerts W.H., Ginsberg J.S. The incidence of symptomatic venous thromboembolism during and after prophylaxis with enoxaparin: a multi-institutional cohort study of patients who underwent hip or knee arthroplasty. Arch Intern Med. 158:1998;873-878.
123. Bauer K.A., Eriksson B.I., Lassen M.R., Turpie A.G. Fondaparinux compared with enoxaparin for the prevention of venous thromboembolism after elective major knee surgery. N Engl J Med. 345:2001;1305-1310.
124. Eriksson B.I., Bauer K.A., Lassen M.R., Turpie A.G. Fondaparinux compared with enoxaparin for the prevention of venous thromboembolism after hip-fracture surgery. N Engl J Med. 345:2001;1298-1304.
125. Pulmonary Embolism Prevention (PEP) Investigators. Prevention of pulmonary embolism and deep vein thrombosis with low dose aspirin. Lancet 2000; 355: 1295-1302.
126. Agnelli G., Piovella F., Buoncristiani P., et al. Enoxaparin plus compression stockings compared with compression stockings alone in the prevention of venous thromboembolism after elective neurosurgery. N Engl J Med. 339:1998;80-85.
127. Comerota A.J., Chouhan V., Harada R.N., et al. The fibrinolytic effects of intermittent pneumatic compression: mechanism of enhanced fibrinolysis. Ann Surg. 226:1997;306-313.
128. International Trial Investigators. Prevention of fatal postoperative pulmonary embolism by low doses of heparin. Lancet 1975; 2: 45-51.
129. Collins R., Scrimgeour A., Yusuf S., Peto R. Reduction in fatal pulmonary embolism and venous thrombosis by perioperative administration of subcutaneous heparin: overview of results of randomized trials in general, orthopedic, and urologic surgery. N Engl J Med. 318:1988;1162-1173.
130. Hull R.D., Pineo G.F., Stein P.D., et al. Timing of initial administration of low-molecular-weight heparin prophylaxis against deep vein thrombosis in patients following elective hip arthroplasty: a systematic review. Arch Intern Med. 161:2001;1952-1960.
131. Lassen M.R., Borris L.C., Nakov R.L. Use of the low-molecular-weight heparin reviparin to prevent deep-vein thrombosis after leg injury requiring immobilization. N Engl J Med. 347:2002;726-730.
132. Turpie A.G., Gallus A.S., Hoek J.A. A synthetic pentasaccharide for the prevention of deep-vein thrombosis after total hip replacement. N Engl J Med. 344:2001;619-625.
133. Bounameaux H., Perneger T. Fondaparinux: a new synthetic pentasaccharide for thrombosis prevention. Lancet. 359:2002;1710-1711.
134. Prandoni P., Bruchi O., Sabbion P., et al. Prolonged thromboprophylaxis with oral anticoagulants after total hip arthroplasty: a prospective controlled randomized study. Arch Intern Med. 162:2002;1966-1971.
135. Antithrombotic Trialists' Collaboration. Collaborative meta-analysis of randomised trials of antiplatelet therapy for prevention of death, myocardial infarction, and stroke in high risk patients. BMJ 2002; 324: 71-86.
136. Bergqvist D., Lindblad B. A 30-year survey of pulmonary embolism verified at autopsy: an analysis of 1274 surgical patients. Br J Surg. 72:1985;105-108.
137. White R.H., Romano P.S., Zhou H., Rodrigo J., Bargar W. Incidence and time course of thromboembolic outcomes following total hip or knee arthroplasty. Arch Intern Med. 158:1998;1525-1531.
138. White R.H., Gettner S., Newman J.M., Trauner K.B., Romano P.S. Predictors of rehospitalization for symptomatic venous thromboembolism after total hip arthroplasty. N Engl J Med. 343:2000;1758-1764.
139. Eikelboom J.W., Quinlan D.J., Douketis J.D. Extended-duration prophylaxis against venous thromboembolism after total hip or knee replacement: a meta-analysis of the randomised trials. Lancet. 358:2001;9-15.
140. Hull R.D., Pineo G.F., Stein P.D., et al. Extended out-of-hospital low-molecular-weight heparin prophylaxis against deep venous thrombosis in patients after elective hip arthroplasty: a systematic review. Ann Intern Med. 135:2001;858-869.
141. Cohen A.T., Bailey C.S., Alikhan R., Cooper D.J. Extended thromboprophylaxis with low molecular weight heparin reduces symptomatic venous thromboembolism following lower limb arthroplasty: a meta-analysis. Thromb Haemost. 85:2001;940-941.
142. Douketis J.D., Eikelboom J.W., Quinlan D.J., Willan A.R., Crowther M.A. Short-duration prophylaxis against venous thromboembolism after total hip or knee replacement: a meta-analysis of prospective studies investigating symptomatic outcomes. Arch Intern Med. 162:2002;1465-1471.
143. Sarasin F.P., Bounameaux H. Out of hospital antithrombotic prophylaxis after total hip replacement: low-molecular-weight heparin, warfarin, aspirin or nothing? A cost-effectiveness analysis. Thromb Haemost. 87:2002;586-592.
144. White R.H., Romano P.S., Zhou H., Rodrigo J., Bargar W. Incidence and time course of thromboembolic outcomes following total hip or knee arthroplasty. Arch Intern Med. 158:1998;1525-1531.